Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383480 | 1.00 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL14218369 | 1.00 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL1581709 | 0.91 | CYP1B1 (0.59) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL5073226 | 0.83 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL19398815 | 0.83 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL23439163 | 0.83 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL17525790 | 0.83 | CYP1B1 (0.56) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL21598051 | 0.83 | CYP1A2 (0.54) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL28872170 | 0.83 | CYP1B1 (0.52) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL30657544 | 0.83 | CYP1B1 (0.56) | CYP1B1CYP1A2CYP2C9CYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9725450-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187479-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440661-B2 | Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-8101588-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2289893-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100249066-A1 | METHODS OF MODULATING INFLAMMATORY CELL RECRUITMENT AND GENE EXPRESSION USING HALOARYL SUBSTITUTED AMINOPURINES | SIGNAL PHARMACEUTICALS, LLC | 2010-09-30 | — | — | US | disclosed |
| US-7759342-B2 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7723340-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090275564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ALBERS RONALD J | 2009-11-05 | — | — | US | disclosed |
| US-7521446-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | CYP1B1 3138/4885CYP1A2 3703/4885CYP2C9 4284/4885 |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | BTK, SYK, LCK | CYP1B1 2197/4885CYP1A2 2978/4885CYP2C9 1568/4885 |
| US-20100249066-A1 | METHODS OF MODULATING INFLAMMATORY CELL RECRUITMENT AND GENE EXPRESSION USING HALOARYL SUBSTITUTED AMINOPURINES | CCR2, CXCR2, CXCR3 | CYP1B1 3886/4885CYP1A2 4430/4885CYP2C9 4575/4885 |
| US-20090275564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | CYP1B1 3179/4885CYP1A2 3655/4885CYP2C9 4308/4885 |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | CYP1B1 3179/4885CYP1A2 3655/4885CYP2C9 4308/4885 |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | CYP1B1 3179/4885CYP1A2 3655/4885CYP2C9 4308/4885 |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | TPMT, MGMT, SMAD3 | CYP1B1 3311/4885CYP1A2 3986/4885CYP2C9 4366/4885 |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | CYP1B1 3179/4885CYP1A2 3655/4885CYP2C9 4308/4885 |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | TPMT, MGMT, SMAD3 | CYP1B1 3489/4885CYP1A2 4055/4885CYP2C9 4452/4885 |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | BTK, SYK, LCK | CYP1B1 2197/4885CYP1A2 2978/4885CYP2C9 1568/4885 |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | CYP1B1 3179/4885CYP1A2 3655/4885CYP2C9 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.